Candel Therapeutics (CADL) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.36

Estimate

-$0.23

Surprise

-52.9%

Score today

4.9/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Candel Therapeutics (CADL) reported a wider loss than forecast — diluted EPS of -$0.36 against the -$0.23 estimate (a 52.9% shortfall).

• B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12 — benzinga, 2026-08-14
• HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target — benzinga, 2026-08-13
• Candel Therapeutics Q2 EPS $(0.52) Misses $(0.23) Estimate — benzinga, 2026-08-13

TrendMatrix currently rates CADL Sell at 4.9/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -52.9% surprise compares with a -14.2% four-quarter average. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$10.90

Price target

$18.27

Stop

$10.25

Upside to target

+67.6%

Reward-to-risk

4.9:1

Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$850.9M

P/E (fwd)

-17.8

52-week range

$4.35–$14.00

Off 52-week high

22.1%

RSI (14)

28

Volume vs avg

0.93×

Score today

4.9/10